Cystic Fibrosis (CF)NCT07770854
Machine Learning Prediction of Pulmonary Function in Children With Cystic Fibrosis
An observational study of Cystic Fibrosis (CF), run by Gazi University at 1 site in Turkey (Türkiye).
Trial summary
Cystic fibrosis is a multisystem genetic disorder characterized by progressive pulmonary impairment and extrapulmonary limitations. This retrospective observational study will perform a secondary analysis of previously collected data from children with cystic fibrosis. Read more about this study
- Who is it for?
- Ages 6 to 18 years
- Conditions the study is for
- Cystic Fibrosis (CF)
- What is being tested?
- Archived Multidimensional Clinical and Functional Assessment Data
- How many people
- 31 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Jan 2021to 1 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: The study population will consist of archived records from children aged 6 to 18 years with cystic fibrosis who were referred by the Division of Pediatric Pulmonology, Gazi University Faculty of Medicine, and evaluated at the Cardiopulmonary Rehabilitation Unit, Department of Physiotherapy and Rehabilitation, Gazi University Faculty of Health Sciences, between April 2021 and September 2022. Only records meeting the prespecified eligibility criteria and containing the variables required for the principal analyses will be included. No new recruitment or participant contact will occur.
Who may be able to join
- Age 6 to 18 years at the time of the source assessment
- Diagnosis of cystic fibrosis according to the criteria specified in the Cystic Fibrosis Foundation consensus report
- Clinically stable at the time of the source assessment
- Receiving standard medical treatment
- Written informed consent/assent from the participant and parent or legal guardian for participation in the source study
- Availability of archived data for the principal variables required for the present analysis
Who cannot join
- Diagnosed visual, hearing, vestibular, or neurological disorder that could affect balance
- Hospitalization within the month preceding the source assessment
- Participation in a structured exercise training program within the 3 months preceding the source assessment
- History of COVID-19 or tobacco use
- Orthopedic disorder affecting mobility or history of musculoskeletal surgery
- Acute pulmonary exacerbation at the time of assessment
Show all 11Show fewer
- Allergic bronchopulmonary aspergillosis
- History of lung or liver transplantation
- Systemic corticosteroid use
- Pulmonary hypertension or cardiovascular instability
- Missing archived records required for the principal analyses
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Gazi University Faculty of Health Sciences Department of Cardiopulmonary Physiotherapy and Rehabilitation, Ankara, Çankaya 06490
Ankara, Ankara, 06560
About this study
Official title: Machine Learning Prediction of Pulmonary Function in Children With Cystic Fibrosis: Multidimensional Analysis of Peripheral Muscle Oxygenation, Postural Balance, and Clinical-Functional Markers
Cystic fibrosis is a multisystem genetic disorder characterized by progressive pulmonary impairment and extrapulmonary limitations. This retrospective observational study will perform a secondary analysis of previously collected data from children with cystic fibrosis. The primary objective is to determine the relative contribution of peripheral muscle oxygenation and postural balance parameters to the prediction of pulmonary function, including forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow, using machine-learning regression methods. The additional contribution of exercise-related oxygen saturation responses, symptoms, nutritional and anthropometric characteristics, physical activity, respiratory muscle function, quality of life, treatment burden, and disease-related clinical variables will also be examined. No new assessment, intervention, or participant contact will occur.
Read the detailed description
This study is a retrospective, cross-sectional, non-interventional secondary analysis of de-identified archived data obtained from children with cystic fibrosis who were evaluated at the Cardiopulmonary Rehabilitation Unit, Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Gazi University, between April 2021 and September 2022.
The source data were collected prospectively as part of a previous observational study approved by the Gazi University Ethics Commission (Decision No. 839, December 7, 2020) and prospectively registered at ClinicalTrials.gov (NCT04803643). Written informed consent was obtained from the participants and their parents or legal guardians before the assessments conducted in the source study. No new participant contact, recruitment, assessment, biological sample collection, or intervention will be performed for the present secondary analysis.
Although the parent study included an age- and sex-matched healthy control group, the present prediction analysis will be restricted to the archived records of 31 children with cystic fibrosis who satisfy the prespecified eligibility criteria and have the variables required for the planned analyses.
Pulmonary Function Outcomes
Pulmonary function was assessed using a COSMED spirometer (Class II/Internally Powered Equipment, Italy) in accordance with American Thoracic Society/European Respiratory Society standardization criteria. Measurements were performed in the seated position using a nose clip. Participants completed at least three technically acceptable forced expiratory maneuvers, and the highest acceptable values were recorded.
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF), expressed as both absolute and percent-predicted values, will constitute the prespecified pulmonary function prediction targets. A separate prediction model will be developed for each pulmonary function target.
Peripheral Muscle Oxygenation
Peripheral muscle oxygenation was assessed noninvasively using the Moxy Monitor, a portable near-infrared spectroscopy device (Fortiori Design LLC, Minnesota, USA). During the six-minute walk test, the sensor was positioned over the quadriceps femoris muscle of the dominant lower extremity and secured in the same position throughout the test.
Muscle oxygen saturation (SmO2) and total hemoglobin (THb) were monitored continuously during the resting, exercise, and recovery periods. The archived measurements included resting, minimum, maximum, and recovery SmO2 and THb values. Changes between resting, exercise, and recovery values will also be calculated when the required measurements are available. These muscle oxygenation variables will be treated as primary candidate predictors.
Functional Exercise Capacity and Oxygen Saturation Response
Functional exercise capacity was assessed using the six-minute walk test in accordance with American Thoracic Society procedures. Participants were instructed to walk, without running, as far as possible along a predetermined level corridor for six minutes. The total distance walked was recorded in meters.
Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, perceived dyspnea, and leg fatigue were assessed before and after the test. Peripheral oxygen saturation was monitored throughout the test, and resting, minimum, end-test, and recovery SpO2 values were recorded. Exercise-related changes in SpO2 will be derived from these archived measurements when appropriate.
Perceived dyspnea and fatigue were evaluated using the Modified Borg Scale, ranging from 0 to 10, with higher scores indicating greater symptom severity. Six-minute walk distance, SpO2 responses, and symptom scores will be evaluated as additional candidate predictors.
Respiratory Muscle Strength
Respiratory muscle strength was assessed using a portable electronic mouth-pressure measurement device in accordance with ATS/ERS recommendations. Maximal inspiratory pressure was measured from a lung volume close to residual volume, whereas maximal expiratory pressure was measured from a lung volume close to total lung capacity.
Participants performed at least three technically acceptable and reproducible maneuvers with verbal encouragement. The highest acceptable maximal inspiratory pressure and maximal expiratory pressure values were recorded in cmH2O. MIP and MEP values were also expressed as percentages of age- and sex-predicted values when available. Absolute and percent-predicted MIP and MEP measurements will be evaluated as additional candidate predictors.
Inspiratory Muscle Endurance
Inspiratory muscle endurance was assessed using an incremental threshold-loading test with the POWERbreathe Wellness device (POWERbreathe International Ltd., Birmingham, United Kingdom). The test was initiated at 20% of the participant's maximal inspiratory pressure. The threshold load was subsequently increased to 40%, 60%, 80%, and 100% of MIP at two-minute intervals.
Participants were instructed to continue breathing against the imposed resistance at each load. The test was terminated if the participant failed to complete three consecutive breaths, could not maintain the required breathing pattern, could not tolerate the load, requested termination, or met a clinical stopping criterion.
The archived respiratory muscle endurance variables included total test duration, number of breaths completed, highest successfully sustained load, and the highest load expressed as a percentage of MIP. These variables will be considered additional candidate predictors.
Static Postural Balance
Static postural balance was assessed using the Biodex Balance System. Testing was performed under four sensory conditions: eyes open on a firm surface, eyes closed on a firm surface, eyes open on a soft surface, and eyes closed on a soft surface.
Each condition was assessed three times for 20 seconds, with a 10-second rest interval between repetitions. Overall Stability Index, Anteroposterior Stability Index, and Mediolateral Stability Index values were recorded. Higher stability index values indicate greater postural sway and poorer postural stability. The stability indices obtained under the different sensory conditions will be treated as primary candidate predictors.
Objectively Measured Physical Activity
Physical activity was assessed objectively using the SenseWear Armband multisensor activity monitor (BodyMedia Inc., Pittsburgh, Pennsylvania, USA). The monitor was positioned over the triceps region of the nondominant upper arm and was worn continuously for three days, except during bathing.
The archived physical activity measurements included daily step count, total energy expenditure, active energy expenditure, physical activity duration, average metabolic equivalent, time spent at different physical activity intensities, sedentary or lying time, and sleep duration. Measurements from valid monitoring days were averaged and processed using SenseWear Software version 7.0. The physical activity variables available in the archived dataset will be evaluated as additional candidate predictors.
Cystic Fibrosis-Specific Quality of Life
Cystic fibrosis-specific health-related quality of life was assessed using the validated Turkish version of the Cystic Fibrosis Questionnaire-Revised. The age-appropriate child, adolescent, or parent-report version was administered in the source study.
The CFQ-R evaluates domains including physical functioning, emotional functioning, social or school functioning, body image, eating problems, treatment burden, health perceptions, weight perceptions, respiratory symptoms, and digestive symptoms, depending on the age-specific questionnaire version. Each domain is transformed to a score ranging from 0 to 100, with higher scores indicating better health-related quality of life. Individual domain scores, rather than an unvalidated overall total score, will be evaluated as additional candidate predictors.
Anthropometric, Nutritional, and Clinical Variables
Archived demographic and anthropometric variables included age, sex, body weight, height, body mass index, weight-for-age Z score, height-for-age Z score, and BMI-for-age Z score. BMI was calculated as body weight in kilograms divided by height in meters squared.
Disease-related clinical characteristics included age at diagnosis, disease duration, pulmonary exacerbations during the preceding year, hospital visits and admissions, medication use, treatment burden, smoking or environmental exposure, and other relevant clinical characteristics available in the archived dataset. These anthropometric, nutritional, demographic, and clinical variables will be evaluated as additional candidate predictors.
Statistical and Machine-Learning Analysis
Separate machine-learning regression models will be developed for the prespecified pulmonary function targets. Peripheral muscle oxygenation and postural balance variables will be treated as the primary candidate predictors. Functional exercise capacity, respiratory muscle strength and endurance, exercise-related oxygen saturation, physical activity, quality of life, anthropometric and nutritional indicators, and disease-related clinical characteristics will be treated as additional candidate predictors.
Categorical variables will be encoded in a form suitable for the selected models. Continuous variables will be examined for implausible values, outliers, distributional characteristics, and strong correlations. The extent and pattern of missing data will be described. Depending on the amount and pattern of missingness, complete-case analysis or an appropriate imputation procedure will be used.
Because of the limited sample size and the relatively large number of candidate predictors, model complexity and the number of variables entering an individual model will be restricted. Parsimonious and regularized regression approaches suitable for small datasets will be prioritized. Alternative low-complexity nonlinear models may be examined only when supported by the available data.
A fixed training-test split will not be used because it would produce very small and potentially unstable subsets. Internal validation will instead be based on cross-validation. All data-dependent preprocessing procedures, including imputation, standardization, variable selection, and hyperparameter tuning, will be performed using the training data within the cross-validation procedure to reduce information leakage and optimistic performance estimates.
Predictive performance will be evaluated using cross-validated R-squared, mean absolute error, and root mean squared error. Higher R-squared values and lower MAE and RMSE values will indicate better predictive performance. The distribution and variability of performance estimates across cross-validation resamples will be examined.
Model-specific variable-importance analyses and, when applicable, variable-selection stability analyses will be used to identify variables that contribute most consistently to prediction. Variable importance will not be interpreted as evidence of a causal relationship. Because the present dataset permits internal validation only, all findings will be interpreted as exploratory and hypothesis-generating, and external validation will be required before any model can be considered for clinical use.
- Conditions
- Cystic Fibrosis (CF)
- Being tested
- Archived Multidimensional Clinical and Functional Assessment Data
- Keywords
- pulmonary function, machine learning, FEV1, FVC, peak expiratory flow, peripheral muscle oxygenation, postural balance, six-minute walk test, physical activity, children
- Medical subject headings
- Cystic Fibrosis, Motor Activity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Archived Multidimensional Clinical and Functional Assessment DataOther
Secondary analysis of archived spirometry, near-infrared spectroscopy, postural balance, exercise capacity, respiratory muscle function, physical activity, quality-of-life, anthropometric, and clinical data. No new assessment or intervention is administered.
| Study group | Role | What they receive |
|---|---|---|
| Children With Cystic Fibrosis | Archived records of children aged 6 to 18 years with cystic fibrosis who underwent multidimensional clinical and functional assessments at the Gazi University Cardiopulmonary Rehabilitation Unit between April 2021 and September 2022. The present study involves secondary data analysis only; no new intervention or assessment will be performed. Receives: Other: Archived Multidimensional Clinical and Functional Assessment Data |
What is being measured
The primary outcome is the main question the study is designed to answer.
Forced Expiratory Volume in 1 Second (FEV1), Absolute Value
FEV1 was measured by spirometry according to ATS/ERS standards and recorded in liters. The highest value from technically acceptable forced expiratory maneuvers was retained. FEV1 will be used as a prespecified pulmonary function prediction target
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Forced Expiratory Volume in 1 Second (FEV1), Percent Predicted
FEV1 expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Forced Vital Capacity (FVC), Absolute Value
FVC was measured by spirometry according to ATS/ERS standards and recorded in liters. The highest value from technically acceptable forced expiratory maneuvers was retained. FVC will be used as a prespecified pulmonary function prediction target.
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Forced Vital Capacity (FVC), Percent Predicted
FVC expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Peak Expiratory Flow (PEF), Absolute Value
PEF was measured by spirometry according to ATS/ERS standards and recorded in [ L/min]. The highest value from technically acceptable forced expiratory maneuvers was retained. PEF will be used as a prespecified pulmonary function prediction target.
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Peak Expiratory Flow (PEF), Percent Predicted
PEF expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
Measured: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
Secondary outcomes (3)
Cross-Validated Predictive Performance of the FEV1 Models
Separate regression models will predict absolute and percent-predicted FEV1. Cross-validated predictive performance will be summarized using R-squared, mean absolute error, and root mean squared error. Higher R-squared and lower error values indicate better predictive performance.
Measured: During analysis of the archived dataset, through study completion (up to 12 months)
Cross-Validated Predictive Performance of the FVC Models
Separate regression models will predict absolute and percent-predicted FVC. Cross-validated predictive performance will be summarized using R-squared, mean absolute error, and root mean squared error. Higher R-squared and lower error values indicate better predictive performance.
Measured: During analysis of the archived dataset, through study completion (up to 12 months)
Cross-Validated Predictive Performance of the PEF Models
Separate regression models will predict absolute and percent-predicted PEF. Cross-validated predictive performance will be summarized using R-squared, mean absolute error, and root mean squared error. Higher R-squared and lower error values indicate better predictive performance.
Measured: During analysis of the archived dataset, through study completion (up to 12 months)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start1 Jan 2021
- Primary completion1 Feb 2025
- Study completion1 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Cystic Fibrosis (CF)Studies of the same condition, open and under way.
- More trials run by Gazi UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 31 participants (actual)
Sponsor and investigators
- Lead sponsor
- Gazi University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Meral Boşnak Güçlü, Gazi University
- Investigators
- Elif KELES GULNERMAN, MD, PhD, Principal investigator, Department of Radiology, Feinberg School of Medicine, Northwestern UniversityMeral BOŞNAK GÜÇLÜ, Prof., Study director, Gazi UniversityBetül Yoleri, MSc, Study chair, Gazi UniversityUlas BAGCI, Prof., Principal investigator, Department of Radiology, Feinberg School of Medicine, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07770854
- Sponsor's protocol ID
- Gazi2907
- Status last verified
- Aug 2026
- First submitted
- 10 Aug 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Dwyer TJ, Alison JA, McKeough ZJ, Elkins MR, Bye PT. Evaluation of the SenseWear activity monitor during exercise in cystic fibrosis and in health. Respir Med. 2009 Oct;103(10):1511-7. doi: 10.1016/j.rmed.2009.04.013. Epub 2009 May 23.
PubMed 19464863Feldmann A, Schmitz R, Erlacher D. Near-infrared spectroscopy-derived muscle oxygen saturation on a 0% to 100% scale: reliability and validity of the Moxy Monitor. J Biomed Opt. 2019 Nov;24(11):1-11. doi: 10.1117/1.JBO.24.11.115001.
PubMed 31741352Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, Dube BP, Fauroux B, Gea J, Guenette JA, Hudson AL, Kabitz HJ, Laghi F, Langer D, Luo YM, Neder JA, O'Donnell D, Polkey MI, Rabinovich RA, Rossi A, Series F, Similowski T, Spengler CM, Vogiatzis I, Verges S. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J. 2019 Jun 13;53(6):1801214. doi: 10.1183/13993003.01214-2018. Print 2019 Jun.
PubMed 30956204American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624. doi: 10.1164/rccm.166.4.518. No abstract available.
PubMed 12186831Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.
PubMed 31613151Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378.
PubMed 38626948Zhou GC, Wang Z, Palipana AK, Andrinopoulou ER, Miranda Afonso P, McPhail GL, Siracusa CM, Gecili E, Szczesniak RD. Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy. Respir Res. 2024 Apr 27;25(1):187. doi: 10.1186/s12931-024-02794-2.
PubMed 38678203Alaa AM, van der Schaar M. Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning. Sci Rep. 2018 Jul 26;8(1):11242. doi: 10.1038/s41598-018-29523-2.
PubMed 30050169Dawson N, Dzurino D, Karleskint M, Tucker J. Examining the reliability, correlation, and validity of commonly used assessment tools to measure balance. Health Sci Rep. 2018 Oct 27;1(12):e98. doi: 10.1002/hsr2.98. eCollection 2018 Dec.
PubMed 30623052Kenis-Coskun O, Karadag-Saygi E, Bahar-Ozdemir Y, Gokdemir Y, Karadag B, Kayhan O. The involvement of musculoskeletal system and its influence on postural stability in children and young adults with cystic fibrosis. Ital J Pediatr. 2017 Nov 21;43(1):106. doi: 10.1186/s13052-017-0426-0.
PubMed 29162121Yoleri B, Bosnak Guclu M, Sismanlar Eyuboglu T, Aslan AT. Peripheral muscle oxygenation during upper extremity functional exercise and balance in pediatric patients with cystic fibrosis: a cross-sectional study. Eur J Appl Physiol. 2026 Jun;126(6):3589-3602. doi: 10.1007/s00421-026-06130-y. Epub 2026 Mar 7.
PubMed 41793435Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med. 1992 Dec 17;327(25):1785-8. doi: 10.1056/NEJM199212173272504.
PubMed 1435933Sovtic A, Minic P, Markovic-Sovtic G, Trajkovic GZ. Respiratory Muscle Strength and Exercise Performance in Cystic Fibrosis-A Cross Sectional Study. Front Pediatr. 2018 Sep 4;6:244. doi: 10.3389/fped.2018.00244. eCollection 2018.
PubMed 30234080Vendrusculo FM, Heinzmann-Filho JP, Piva TC, Marostica PJ, Donadio MV. Inspiratory Muscle Strength and Endurance in Children and Adolescents with Cystic Fibrosis. Respir Care. 2016 Feb;61(2):184-91. doi: 10.4187/respcare.04231. Epub 2015 Nov 24.
PubMed 26604327Werkman M, Jeneson J, Helders P, Arets B, van der Ent K, Velthuis B, Nievelstein R, Takken T, Hulzebos E. Exercise oxidative skeletal muscle metabolism in adolescents with cystic fibrosis. Exp Physiol. 2016 Mar;101(3):421-31. doi: 10.1113/EP085425.
PubMed 26707538
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Machine Learning Prediction of Pulmonary Function in Children With Cystic Fibrosis: Multidimensional Analysis of Peripheral Muscle Oxygenation, Postural Balance, and Clinical-Functional Markers
- ClinicalTrials.gov ID
- NCT07770854
- Acronym / sponsor ID
- Gazi2907
- Conditions
- Cystic Fibrosis (CF)
- Keywords
- pulmonary function, machine learning, FEV1, FVC, peak expiratory flow, peripheral muscle oxygenation, postural balance, six-minute walk test
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 31 participants (actual)
- Lead sponsor
- Gazi UniversityUniversity, hospital or other
- Study start
- 1 Jan 2021 (actual)
- Primary completion
- 1 Feb 2025 (actual)
- Study completion
- 1 Mar 2025 (actual)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Cystic fibrosis is a multisystem genetic disorder characterized by progressive pulmonary impairment and extrapulmonary limitations. This retrospective observational study will perform a secondary analysis of previously collected data from children with cystic fibrosis. The primary objective is to determine the relative contribution of peripheral muscle oxygenation and postural balance parameters to the prediction of pulmonary function, including forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow, using machine-learning regression methods. The additional contribution of exercise-related oxygen saturation responses, symptoms, nutritional and anthropometric characteristics, physical activity, respiratory muscle function, quality of life, treatment burden, and disease-related clinical variables will also be examined. No new assessment, intervention, or participant contact will occur.
Detailed description
This study is a retrospective, cross-sectional, non-interventional secondary analysis of de-identified archived data obtained from children with cystic fibrosis who were evaluated at the Cardiopulmonary Rehabilitation Unit, Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Gazi University, between April 2021 and September 2022.
The source data were collected prospectively as part of a previous observational study approved by the Gazi University Ethics Commission (Decision No. 839, December 7, 2020) and prospectively registered at ClinicalTrials.gov (NCT04803643). Written informed consent was obtained from the participants and their parents or legal guardians before the assessments conducted in the source study. No new participant contact, recruitment, assessment, biological sample collection, or intervention will be performed for the present secondary analysis.
Although the parent study included an age- and sex-matched healthy control group, the present prediction analysis will be restricted to the archived records of 31 children with cystic fibrosis who satisfy the prespecified eligibility criteria and have the variables required for the planned analyses.
Pulmonary Function Outcomes
Pulmonary function was assessed using a COSMED spirometer (Class II/Internally Powered Equipment, Italy) in accordance with American Thoracic Society/European Respiratory Society standardization criteria. Measurements were performed in the seated position using a nose clip. Participants completed at least three technically acceptable forced expiratory maneuvers, and the highest acceptable values were recorded.
Forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow (PEF), expressed as both absolute and percent-predicted values, will constitute the prespecified pulmonary function prediction targets. A separate prediction model will be developed for each pulmonary function target.
Peripheral Muscle Oxygenation
Peripheral muscle oxygenation was assessed noninvasively using the Moxy Monitor, a portable near-infrared spectroscopy device (Fortiori Design LLC, Minnesota, USA). During the six-minute walk test, the sensor was positioned over the quadriceps femoris muscle of the dominant lower extremity and secured in the same position throughout the test.
Muscle oxygen saturation (SmO2) and total hemoglobin (THb) were monitored continuously during the resting, exercise, and recovery periods. The archived measurements included resting, minimum, maximum, and recovery SmO2 and THb values. Changes between resting, exercise, and recovery values will also be calculated when the required measurements are available. These muscle oxygenation variables will be treated as primary candidate predictors.
Functional Exercise Capacity and Oxygen Saturation Response
Functional exercise capacity was assessed using the six-minute walk test in accordance with American Thoracic Society procedures. Participants were instructed to walk, without running, as far as possible along a predetermined level corridor for six minutes. The total distance walked was recorded in meters.
Heart rate, blood pressure, respiratory rate, peripheral oxygen saturation, perceived dyspnea, and leg fatigue were assessed before and after the test. Peripheral oxygen saturation was monitored throughout the test, and resting, minimum, end-test, and recovery SpO2 values were recorded. Exercise-related changes in SpO2 will be derived from these archived measurements when appropriate.
Perceived dyspnea and fatigue were evaluated using the Modified Borg Scale, ranging from 0 to 10, with higher scores indicating greater symptom severity. Six-minute walk distance, SpO2 responses, and symptom scores will be evaluated as additional candidate predictors.
Respiratory Muscle Strength
Respiratory muscle strength was assessed using a portable electronic mouth-pressure measurement device in accordance with ATS/ERS recommendations. Maximal inspiratory pressure was measured from a lung volume close to residual volume, whereas maximal expiratory pressure was measured from a lung volume close to total lung capacity.
Participants performed at least three technically acceptable and reproducible maneuvers with verbal encouragement. The highest acceptable maximal inspiratory pressure and maximal expiratory pressure values were recorded in cmH2O. MIP and MEP values were also expressed as percentages of age- and sex-predicted values when available. Absolute and percent-predicted MIP and MEP measurements will be evaluated as additional candidate predictors.
Inspiratory Muscle Endurance
Inspiratory muscle endurance was assessed using an incremental threshold-loading test with the POWERbreathe Wellness device (POWERbreathe International Ltd., Birmingham, United Kingdom). The test was initiated at 20% of the participant's maximal inspiratory pressure. The threshold load was subsequently increased to 40%, 60%, 80%, and 100% of MIP at two-minute intervals.
Participants were instructed to continue breathing against the imposed resistance at each load. The test was terminated if the participant failed to complete three consecutive breaths, could not maintain the required breathing pattern, could not tolerate the load, requested termination, or met a clinical stopping criterion.
The archived respiratory muscle endurance variables included total test duration, number of breaths completed, highest successfully sustained load, and the highest load expressed as a percentage of MIP. These variables will be considered additional candidate predictors.
Static Postural Balance
Static postural balance was assessed using the Biodex Balance System. Testing was performed under four sensory conditions: eyes open on a firm surface, eyes closed on a firm surface, eyes open on a soft surface, and eyes closed on a soft surface.
Each condition was assessed three times for 20 seconds, with a 10-second rest interval between repetitions. Overall Stability Index, Anteroposterior Stability Index, and Mediolateral Stability Index values were recorded. Higher stability index values indicate greater postural sway and poorer postural stability. The stability indices obtained under the different sensory conditions will be treated as primary candidate predictors.
Objectively Measured Physical Activity
Physical activity was assessed objectively using the SenseWear Armband multisensor activity monitor (BodyMedia Inc., Pittsburgh, Pennsylvania, USA). The monitor was positioned over the triceps region of the nondominant upper arm and was worn continuously for three days, except during bathing.
The archived physical activity measurements included daily step count, total energy expenditure, active energy expenditure, physical activity duration, average metabolic equivalent, time spent at different physical activity intensities, sedentary or lying time, and sleep duration. Measurements from valid monitoring days were averaged and processed using SenseWear Software version 7.0. The physical activity variables available in the archived dataset will be evaluated as additional candidate predictors.
Cystic Fibrosis-Specific Quality of Life
Cystic fibrosis-specific health-related quality of life was assessed using the validated Turkish version of the Cystic Fibrosis Questionnaire-Revised. The age-appropriate child, adolescent, or parent-report version was administered in the source study.
The CFQ-R evaluates domains including physical functioning, emotional functioning, social or school functioning, body image, eating problems, treatment burden, health perceptions, weight perceptions, respiratory symptoms, and digestive symptoms, depending on the age-specific questionnaire version. Each domain is transformed to a score ranging from 0 to 100, with higher scores indicating better health-related quality of life. Individual domain scores, rather than an unvalidated overall total score, will be evaluated as additional candidate predictors.
Anthropometric, Nutritional, and Clinical Variables
Archived demographic and anthropometric variables included age, sex, body weight, height, body mass index, weight-for-age Z score, height-for-age Z score, and BMI-for-age Z score. BMI was calculated as body weight in kilograms divided by height in meters squared.
Disease-related clinical characteristics included age at diagnosis, disease duration, pulmonary exacerbations during the preceding year, hospital visits and admissions, medication use, treatment burden, smoking or environmental exposure, and other relevant clinical characteristics available in the archived dataset. These anthropometric, nutritional, demographic, and clinical variables will be evaluated as additional candidate predictors.
Statistical and Machine-Learning Analysis
Separate machine-learning regression models will be developed for the prespecified pulmonary function targets. Peripheral muscle oxygenation and postural balance variables will be treated as the primary candidate predictors. Functional exercise capacity, respiratory muscle strength and endurance, exercise-related oxygen saturation, physical activity, quality of life, anthropometric and nutritional indicators, and disease-related clinical characteristics will be treated as additional candidate predictors.
Categorical variables will be encoded in a form suitable for the selected models. Continuous variables will be examined for implausible values, outliers, distributional characteristics, and strong correlations. The extent and pattern of missing data will be described. Depending on the amount and pattern of missingness, complete-case analysis or an appropriate imputation procedure will be used.
Because of the limited sample size and the relatively large number of candidate predictors, model complexity and the number of variables entering an individual model will be restricted. Parsimonious and regularized regression approaches suitable for small datasets will be prioritized. Alternative low-complexity nonlinear models may be examined only when supported by the available data.
A fixed training-test split will not be used because it would produce very small and potentially unstable subsets. Internal validation will instead be based on cross-validation. All data-dependent preprocessing procedures, including imputation, standardization, variable selection, and hyperparameter tuning, will be performed using the training data within the cross-validation procedure to reduce information leakage and optimistic performance estimates.
Predictive performance will be evaluated using cross-validated R-squared, mean absolute error, and root mean squared error. Higher R-squared values and lower MAE and RMSE values will indicate better predictive performance. The distribution and variability of performance estimates across cross-validation resamples will be examined.
Model-specific variable-importance analyses and, when applicable, variable-selection stability analyses will be used to identify variables that contribute most consistently to prediction. Variable importance will not be interpreted as evidence of a causal relationship. Because the present dataset permits internal validation only, all findings will be interpreted as exploratory and hypothesis-generating, and external validation will be required before any model can be considered for clinical use.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Children With Cystic Fibrosis | – | Other: Archived Multidimensional Clinical and Functional Assessment DataArchived records of children aged 6 to 18 years with cystic fibrosis who underwent multidimensional clinical and functional assessments at the Gazi University Cardiopulmonary Rehabilitation Unit between April 2021 and September 2022. The present study involves secondary data analysis only; no new intervention or assessment will be performed. |
Who may qualify
- Ages
- 6 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- The study population will consist of archived records from children aged 6 to 18 years with cystic fibrosis who were referred by the Division of Pediatric Pulmonology, Gazi University Faculty of Medicine, and evaluated at the Cardiopulmonary Rehabilitation Unit, Department of Physiotherapy and Rehabilitation, Gazi University Faculty of Health Sciences, between April 2021 and September 2022. Only records meeting the prespecified eligibility criteria and containing the variables required for the principal analyses will be included. No new recruitment or participant contact will occur.
Key inclusion criteria (6 listed)
- Age 6 to 18 years at the time of the source assessment
- Diagnosis of cystic fibrosis according to the criteria specified in the Cystic Fibrosis Foundation consensus report
- Clinically stable at the time of the source assessment
- Receiving standard medical treatment
- Written informed consent/assent from the participant and parent or legal guardian for participation in the source study
Key exclusion criteria (11 listed)
- Diagnosed visual, hearing, vestibular, or neurological disorder that could affect balance
- Hospitalization within the month preceding the source assessment
- Participation in a structured exercise training program within the 3 months preceding the source assessment
- History of COVID-19 or tobacco use
- Orthopedic disorder affecting mobility or history of musculoskeletal surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Archived Multidimensional Clinical and Functional Assessment DataSecondary analysis of archived spirometry, near-infrared spectroscopy, postural balance, exercise capacity, respiratory muscle function, physical activity, quality-of-life, anthropometric, and clinical data. No new assessment or intervention is administered. | Other | Children With Cystic Fibrosis |
Primary outcome
Forced Expiratory Volume in 1 Second (FEV1), Absolute Value
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
FEV1 was measured by spirometry according to ATS/ERS standards and recorded in liters. The highest value from technically acceptable forced expiratory maneuvers was retained. FEV1 will be used as a prespecified pulmonary function prediction target
Forced Expiratory Volume in 1 Second (FEV1), Percent Predicted
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
FEV1 expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
Forced Vital Capacity (FVC), Absolute Value
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
FVC was measured by spirometry according to ATS/ERS standards and recorded in liters. The highest value from technically acceptable forced expiratory maneuvers was retained. FVC will be used as a prespecified pulmonary function prediction target.
Forced Vital Capacity (FVC), Percent Predicted
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
FVC expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
Peak Expiratory Flow (PEF), Absolute Value
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
PEF was measured by spirometry according to ATS/ERS standards and recorded in [ L/min]. The highest value from technically acceptable forced expiratory maneuvers was retained. PEF will be used as a prespecified pulmonary function prediction target.
Peak Expiratory Flow (PEF), Percent Predicted
Time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)
PEF expressed as percent of the age-, sex-, and body-size-appropriate predicted value will be used as a prespecified pulmonary function prediction target. Higher values indicate better pulmonary function.
3 secondary outcomes
Cross-Validated Predictive Performance of the FEV1 Models
Time frame: During analysis of the archived dataset, through study completion (up to 12 months)
Cross-Validated Predictive Performance of the FVC Models
Time frame: During analysis of the archived dataset, through study completion (up to 12 months)
Cross-Validated Predictive Performance of the PEF Models
Time frame: During analysis of the archived dataset, through study completion (up to 12 months)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Results publication: PubMed 19464863Dwyer TJ, Alison JA, McKeough ZJ, Elkins MR, Bye PT. Evaluation of the SenseWear activity monitor during exercise in cystic fibrosis and in health. Respir Med. 2009 Oct;103(10):1511-7. doi: 10.1016/j.rmed.2009.04.013. Epub 2009 May 23.
- Results publication: PubMed 31741352Feldmann A, Schmitz R, Erlacher D. Near-infrared spectroscopy-derived muscle oxygen saturation on a 0% to 100% scale: reliability and validity of the Moxy Monitor. J Biomed Opt. 2019 Nov;24(11):1-11. doi: 10.1117/1.JBO.24.11.115001.
- Results publication: PubMed 30956204Laveneziana P, Albuquerque A, Aliverti A, Babb T, Barreiro E, Dres M, Dube BP, Fauroux B, Gea J, Guenette JA, Hudson AL, Kabitz HJ, Laghi F, Langer D, Luo YM, Neder JA, O'Donnell D, Polkey MI, Rabinovich RA, Rossi A, Series F, Similowski T, Spengler CM, Vogiatzis I, Verges S. ERS statement on respiratory muscle testing at rest and during exercise. Eur Respir J. 2019 Jun 13;53(6):1801214. doi: 10.1183/13993003.01214-2018. Print 2019 Jun.
- Results publication: PubMed 12186831American Thoracic Society/European Respiratory Society. ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med. 2002 Aug 15;166(4):518-624. doi: 10.1164/rccm.166.4.518. No abstract available.
- Results publication: PubMed 31613151Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, Hallstrand TS, Kaminsky DA, McCarthy K, McCormack MC, Oropez CE, Rosenfeld M, Stanojevic S, Swanney MP, Thompson BR. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.
- Results publication: PubMed 38626948Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378.
- Results publication: PubMed 38678203Zhou GC, Wang Z, Palipana AK, Andrinopoulou ER, Miranda Afonso P, McPhail GL, Siracusa CM, Gecili E, Szczesniak RD. Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy. Respir Res. 2024 Apr 27;25(1):187. doi: 10.1186/s12931-024-02794-2.
- Results publication: PubMed 30050169Alaa AM, van der Schaar M. Prognostication and Risk Factors for Cystic Fibrosis via Automated Machine Learning. Sci Rep. 2018 Jul 26;8(1):11242. doi: 10.1038/s41598-018-29523-2.
- Results publication: PubMed 30623052Dawson N, Dzurino D, Karleskint M, Tucker J. Examining the reliability, correlation, and validity of commonly used assessment tools to measure balance. Health Sci Rep. 2018 Oct 27;1(12):e98. doi: 10.1002/hsr2.98. eCollection 2018 Dec.
- Results publication: PubMed 29162121Kenis-Coskun O, Karadag-Saygi E, Bahar-Ozdemir Y, Gokdemir Y, Karadag B, Kayhan O. The involvement of musculoskeletal system and its influence on postural stability in children and young adults with cystic fibrosis. Ital J Pediatr. 2017 Nov 21;43(1):106. doi: 10.1186/s13052-017-0426-0.
- Results publication: PubMed 41793435Yoleri B, Bosnak Guclu M, Sismanlar Eyuboglu T, Aslan AT. Peripheral muscle oxygenation during upper extremity functional exercise and balance in pediatric patients with cystic fibrosis: a cross-sectional study. Eur J Appl Physiol. 2026 Jun;126(6):3589-3602. doi: 10.1007/s00421-026-06130-y. Epub 2026 Mar 7.
- Results publication: PubMed 1435933Nixon PA, Orenstein DM, Kelsey SF, Doershuk CF. The prognostic value of exercise testing in patients with cystic fibrosis. N Engl J Med. 1992 Dec 17;327(25):1785-8. doi: 10.1056/NEJM199212173272504.
- Individual participant dataSharing planned: No
Related trials for Cystic Fibrosis (CF)
Active, not recruiting
Personalized Mobile Health Platform to Promote Physical Activity in Adolescents and Young Adults With Cystic Fibrosis
Cystic Fibrosis (CF)
RecruitingObservational study
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
Cystic Fibrosis (CF)
Active, not recruitingObservational study
Genetic Modifiers of Cystic Fibrosis (CF) Liver Disease
Cystic Fibrosis, Liver Disease
Recruiting
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
Non-cystic Fibrosis Bronchiectasis
RecruitingPhase 2
Phase 2 Study to Assess the Safety and Efficacy of ANG003
Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Elif KELES GULNERMAN, MD, PhD principal investigator
Department of Radiology, Feinberg School of Medicine, Northwestern University
Meral BOŞNAK GÜÇLÜ, Prof. study director
Gazi University
Betül Yoleri, MSc study chair
Gazi University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cystic Fibrosis (CF), run by Gazi University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Forced Expiratory Volume in 1 Second (FEV1), Absolute Value (time frame: At the single archived cross-sectional assessment (data originally collected between April 2021 and September 2022)). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07770854, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.